Since Day 1, the company has regarded innovation and R&D as the ‘lifeline’ of its development. Relying on talent, capital, industry-academia-research integrated cooperation, advanced equipment and a rich pipeline of R&D projects, the company has built a high level R&D system empowering sustainable and high quality development.

Elite Team
Talent serves as the cornerstone that guarantees innovation. With a team of 24 professionals including 3 PhD and 5 Master Degree holders, our R&D team covers core areas such as Bio-pharmaceuticals, Medicinal Chemistry, Pharmaceutics, etc, providing talent support for the scientific rigor and efficiency of R&D projects with a forward-looking vision.

Continuous Capital Investment
Safeguard R&D and enhance motivation. Since 2024, the company’s R&D expenditure has increased to around 25% of its sales revenue, far exceeding industry average. Funds are used for equipment upgrade, project development, talent cultivation and technological breakthroughs, which guarantees the leadership of our next generation products in the industry. 

Deep Industry-Academia-Research Cooperation
By integrating different resources, the company has streamlined the innovation chain from production to education, research and application. The company has established long-term cooperation with China Pharmaceutical University, Southeast University, Nanjing University of Chinese Medicine and Jiangnan University. By combining the scientific research resources of these universities with our industrialization capabilities, the company aims to overcome technical challenges, accelerate the transformation of research results and provide external support for its R&D pipelines.

Advanced Equipment
Hardware empowerment to create a high-level R&D platform. Our State-of-the-Art Lab is equipped with cutting edge apparatus including: HPLC, HPGC, Protein Electrophoresis Apparatus, ELISA Microplate Reader, Nucleic Acid Electrophoresis Apparatus, Spectrophotometers, High-speed Refrigerated Centrifuge, etc, covering core areas such as component analysis and molecular biology research, and capable of completing full cycle experiment for pharmaceutical research with efficient progress and accurate data. 

Diversified R&D Pipelines
Focus on clinical applications and develop a diversified portfolio. The company currently has 9 generic drugs, 4 new drugs in 1.1 Class and 1 secondary class medical device under development. 

In the future, we will continue to increase investment in R&D, deepen industry-academia-research cooperation, improve technology platform, promote the launch of more high-quality pharmaceutical products, and contribute to the innovation of the pharmaceutical industry.